Update on thyroid cancer treatment

Future Oncology

Volumn 8, Issue 10, 2012, Pages 1331-1348

  Regalbuto, Concetto ^a   Frasca, Francesco ^a   Pellegriti, Gabriella ^a   Malandrino, Pasqualino ^a   Marturano, Ilenia ^a   Di Carlo, Isidoro ^a   Pezzino, Vincenzo ^a,b  

^a UNIVERSITY OF CATANIA   (Italy)

^b CANNIZZARO HOSPITAL   (Italy)

Author keywords

anaplastic thyroid carcinoma; follicular thyroid carcinoma; medullary thyroid carcinoma; papillary thyroid carcinoma; thyroid cancer treatment

Indexed keywords

AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENT; AXITINIB; BLEOMYCIN; CALCITONIN; CARBOPLATIN; CISPLATIN; CLM 94; COMBRETASTATIN A4 PHOSPHATE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; GEFITINIB; IMATINIB; KETOCONAZOLE; LENVATINIB; METHOTREXATE; METYRAPONE; MIFEPRISTONE; MITOTANE; MOTESANIB; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PACLITAXEL; PAZOPANIB; RADIOACTIVE IODINE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ABDOMINAL PAIN; ADRENALECTOMY; ANOREXIA; ARTHRALGIA; BLEEDING; CALCITONIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CUSHING SYNDROME; DIARRHEA; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; DRUG ERUPTION; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; GALLBLADDER DISEASE; HAND FOOT SYNDROME; HEADACHE; HEALTH CARE COST; HUMAN; HYPERTENSION; INCIDENCE; LEUKOPENIA; MOLECULARLY TARGETED THERAPY; NAUSEA; OPERATION DURATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RADIOFREQUENCY ABLATION; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THYROID CANCER; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA; CLINICAL TRIALS AS TOPIC; HORMONE REPLACEMENT THERAPY; HUMANS; IODINE RADIOISOTOPES; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; THYROID GLAND; THYROID NEOPLASMS;

EID: 84868537517     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.123     Document Type: Review

References (163)

1. Livolsi VA, Albores-Saavedra J, Asa SL. Papillary carcinoma. In: Pathology and Genetics of Tumours of the Endocrine Organs. World Health Organization Classification of Tumours. De Lellis RA, Lloyd RV, Heitz PU, Eng C (Eds IARC Press, Lyon, France 57-66 (2004
2. Regalbuto C, Malandrino P, Tumminia A, Le Moli R, Vigneri R, Pezzino V. A diffuse sclerosing variant of papillary thyroid carcinoma: Clinical and pathologic features and outcomes of 34 consecutive cases. Thyroid 21(4), 383-389 (2011
3. Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A. Aggressive variants of papillary thyroid carcinoma. Head Neck 33(7), 1052-1059 (2011
4. Regalbuto C, Malandrino P, Frasca F et al. The tall cell variant of papillary thyroid carcinoma: Clinical and pathological features and outcomes. J. End Invest. (2012) (Epub ahead of print
5. Emerick GT, Duh QY, Siperstein AE, Burrow GN, Clark OH. Diagnosis, treatment, and outcome of follicular thyroid carcinoma. Cancer 72(11), 3287-3295 (1993 (Pubitemid 23356775)
6. Simpson WJ, Mckinney SE, Carruthers JS, Gospodarowicz MK, Sutcliffe SB, Panzarella T. Papillary and follicular thyroid cancer. Prognostic factors in 1,578 patients. Am. J. Med. 83(3), 479-488 (1987
7. Al-Rawi M, Wheeler MH. Medullary thyroid carcinoma - update and present management controversies. Ann. R. Coll. Surg. Engl. 88(5), 433-438 (2006 (Pubitemid 44390349)
8. De Groot JW, Plukker JT, Wolffenbuttel BH, Wiggers T, Sluiter WJ, Links TP. Determinants of life expectancy in medullary thyroid cancer: Age does not matter. Clin. Endocrinol. (Oxf.). 65(6), 729-736 (2006 (Pubitemid 44772352)
9. Ain KB. Anaplastic thyroid carcinoma: A therapeutic challenge. Semin. Surg. Oncol. 16(1), 64-69 (1999
10. Tan RK, Finley RK 3rd, Driscoll D, Bakamjian V, Hicks WL Jr, Shedd DP. Anaplastic carcinoma of the thyroid: A 24-year experience. Head Neck 17(1), 41-47; discussion 47-48 (1995
11. Kilfoy BA, Zheng T, Holford TR et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 20(5), 525-531 (2009
12. Enewold L, Zhu K, Ron E et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol. Biomarkers Prev. 18(3), 784-791 (2009
13. Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ 177(11), 1357-1361 (2007 (Pubitemid 350207190)
14. Yu GP, Li JC, Branovan D, Mccormick S, Schantz SP. Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups. Thyroid 20(5), 465-473 (2010
15. Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167-1214 (2009
16. Luster M, Clarke SE, Dietlein M et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 35(10), 1941-1959 (2008
17. Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), V214-V219 (2010
18. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154(6), 787-803 (2006 (Pubitemid 43997716)
19. Cross S, Wei JP, Kim S, Brams DM. Selective surgery and adjuvant therapy based on risk classifications of well-differentiated thyroid cancer. J. Surg. Oncol. 94(8), 678-682 (2006 (Pubitemid 44902066)
20. Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control 7(3), 229-239 (2000 (Pubitemid 30387658)
21. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114(6), 1050-1057; discussion 1057-1058 (1993
22. Shah JP, Loree TR, Dharker D, Strong EW, Begg C, Vlamis V. Prognostic factors in differentiated carcinoma of the thyroid gland. Am. J. Surg. 164(6), 658-661 (1992
23. Bilimoria KY, Bentrem DJ, Ko CY et al. Extent of surgery affects survival for papillary thyroid cancer. Ann. Surg. 246(3), 375-381; discussion 381-384 (2007 (Pubitemid 47312122)
24. Iyer NG, Shaha AR. Management of thyroid nodules and surgery for differentiated thyroid cancer. Clin. Oncol. (R. Coll. Radiol.) 22(6), 405-412 (2010
25. Mendelsohn AH, Elashoff DA, Abemayor E, St John MA. Surgery for papillary thyroid carcinoma: Is lobectomy enough? Arch. Otolaryngol. Head Neck Surg. 136(11), 1055-1061 (2010
26. Fritze D, Doherty GM. Surgical management of cervical lymph nodes in differentiated thyroid cancer. Otolaryngol. Clin. North Am. 43(2), 285-300, viii (2010
27. Roh JL, Kim JM, Park CI. Central lymph node metastasis of unilateral papillary thyroid carcinoma: Patterns and factors predictive of nodal metastasis, morbidity, and recurrence. Ann. Surg. Oncol. 18(8), 2245-2250 (2011
28. Dhiman SV, Inabnet WB. Minimally invasive surgery for thyroid diseases and thyroid cancer. J. Surg. Oncol. 97(8), 665-668 (2008 (Pubitemid 351812967)
29. Akslen LA, Livolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer 88(8), 1902-1908 (2000 (Pubitemid 30213001)
30. Bachelot A, Cailleux AF, Klain M et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 12(8), 707-711 (2002 (Pubitemid 34913243)
31. Kim TY, Kim WB, Kim ES et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 90(3), 1440-1445 (2005
32. Rouxel A, Hejblum G, Bernier MO et al. Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 89(11), 5362-5368 (2004 (Pubitemid 39518409)
33. Schlumberger M, Berg G, Cohen O et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: A European perspective. Eur. J. Endocrinol. 150(2), 105-112 (2004 (Pubitemid 38312801)
34. Toubeau M, Touzery C, Arveux P et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. J. Nucl. Med. 45(6), 988-994 (2004 (Pubitemid 47611686)
35. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97(5), 418-428 (1994 (Pubitemid 24345593)
36. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J. Clin. Endocrinol. Metab. 86(4), 1447-1463 (2001 (Pubitemid 32374886)
37. Hod N, Hagag P, Baumer M, Sandbank J, Horne T. Differentiated thyroid carcinoma in children and young adults: Evaluation of response to treatment. Clin. Nucl. Med. 30(6), 387-390 (2005 (Pubitemid 40733995)
38. Ilgan S, Karacalioglu AO, Pabuscu Y et al. Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 31(6), 825-830 (2004 (Pubitemid 38758352)
39. Ronga G, Filesi M, Montesano T et al. Lung metastases from differentiated thyroid carcinoma. A 40 years' experience. Q. J. Nucl. Med. Mol. Imaging 48(1), 12-19 (2004 (Pubitemid 39069659)
40. Bernier MO, Leenhardt L, Hoang C et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 86(4), 1568-1573 (2001 (Pubitemid 32374905)
41. Posteraro AF, Dupuy DE, Mayo-Smith WW. Radiofrequency ablation of bony metastatic disease. Clin. Radiol. 59(9), 803-811 (2004 (Pubitemid 39232915)
42. Schlumberger M, Challeton C, De Vathaire F et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J. Nucl. Med. 37(4), 598-605 (1996 (Pubitemid 126618447)
43. Van Tol KM, Hew JM, Jager PL, Vermey A, Dullaart RP, Links TP. Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma. Clin. Endocrinol. (Oxf.). 52(5), 653-659 (2000 (Pubitemid 30337093)
44. Vitale G, Fonderico F, Martignetti A et al. Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br. J. Cancer 84(12), 1586-1590 (2001 (Pubitemid 32612487)
45. De Keizer B, Brans B, Hoekstra A et al. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. Eur. J. Nucl. Med. Mol. Imaging 30(3), 367-373 (2003 (Pubitemid 36692861)
46. Robbins RJ, Driedger A, Magner J. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 16(11), 1121-1130 (2006 (Pubitemid 44864487)
47. Lassmann M, Reiners C, Luster M. Dosimetry and thyroid cancer: The individual dosage of radioiodine. Endocr. Relat. Cancer 17(3), R161-R172 (2010
48. Verburg FA, Hanscheid H, Biko J et al. Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: Initial experience. Eur. J. Nucl. Med. Mol. Imaging 37(5), 896-903 (2010
49. Mcgriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F, Sarlis NJ. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann. Med. 34(7-8), 554-564 (2002 (Pubitemid 36113813)
50. Cooper DS, Specker B, Ho M et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8(9), 737-744 (1998 (Pubitemid 28535681)
51. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 81(12), 4318-4323 (1996 (Pubitemid 26412036)
52. Sawin CT, Geller A, Wolf PA et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N. Engl. J. Med. 331(19), 1249-1252 (1994 (Pubitemid 24333188)
53. Toft AD. Clinical practice. Subclinical hyperthyroidism. N. Engl. J. Med. 345(7), 512-516 (2001
54. Kebebew E, Greenspan FS, Clark OH, Woeber KA, Mcmillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103(7), 1330-1335 (2005 (Pubitemid 40410726)
55. Akslen LA, Haldorsen T, Thoresen SO, Glattre E. Incidence of thyroid cancer in Norway 1970-1985. Population review on time trend, sex, age, histological type and tumour stage in 2625 cases. APMIS 98(6), 549-558 (1990 (Pubitemid 20239175)
56. Nel CJ, Van Heerden JA, Goellner JR et al. Anaplastic carcinoma of the thyroid: A clinicopathologic study of 82 cases. Mayo Clin. Proc. 60(1), 51-58 (1985 (Pubitemid 15199625)
57. Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC. Anaplastic thyroid cancer: A review of epidemiology, pathogenesis, and treatment. J. Oncol. 2011, 542358 (2011
58. Mciver B, Hay ID, Giuffrida DF et al. Anaplastic thyroid carcinoma: A 50-year experience at a single institution. Surgery 130(6), 1028-1034 (2001 (Pubitemid 34014569)
59. Derbel O, Limem S, Segura-Ferlay C et al. Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer 11, 469 (2011
60. Chang HS, Nam KH, Chung WY, Park CS. Anaplastic thyroid carcinoma: A therapeutic dilemma. Yonsei Med. J. 46(6), 759-764 (2005 (Pubitemid 43085177)
61. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J. Surg. 25(5), 617-622 (2001 (Pubitemid 32441436)
62. Haigh PI, Ituarte PH, Wu HS et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91(12), 2335-2342 (2001 (Pubitemid 32552820)
63. Posner MD, Quivey JM, Akazawa PF, Xia P, Akazawa C, Verhey LJ. Dose optimization for the treatment of anaplastic thyroid carcinoma: A comparison of treatment planning techniques. Int. J. Radiat. Oncol. Biol. Phys. 48(2), 475-483 (2000
64. Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: Current diagnosis and treatment. Ann. Oncol. 11(9), 1083-1089 (2000
65. Lu WT, Lin JD, Huang HS, Chao TC. Does surgery improve the survival of patients with advanced anaplastic thyroid carcinoma? Otolaryngol. Head Neck Surg. 118(5), 728-731 (1998
66. Veness MJ, Porter GS, Morgan GJ. Anaplastic thyroid carcinoma: Dismal outcome despite current treatment approach. ANZ J. Surg. 74(7), 559-562 (2004 (Pubitemid 39006078)
67. Tennvall J, Lundell G, Wahlberg P et al. Anaplastic thyroid carcinoma: Three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br. J. Cancer 86(12), 1848-1853 (2002
68. Ain KB, Egorin MJ, Desimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10(7), 587-594 (2000 (Pubitemid 30670619)
69. Swaak-Kragten AT, De Wilt JH, Schmitz PI, Bontenbal M, Levendag PC. Multimodality treatment for anaplastic thyroid carcinoma - treatment outcome in 75 patients. Radiother. Oncol. 92(1), 100-104 (2009
70. Brierley JD. Update on external beam radiation therapy in thyroid cancer. J. Clin. Endocrinol. Metab. 96(8), 2289-2295 (2011
71. Capdevila J, Iglesias L, Halperin I et al. Sorafenib in metastatic thyroid cancer. Endocr. Relat. Cancer 19(2), 209-216 (2012
72. Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol. 26(29), 4714-4719 (2008
73. Kloos RT, Ringel MD, Knopp MV et al. Phase II trial of sorafenib in metastatic thyroid cancer. J. Clin. Oncol. 27(10), 1675-1684 (2009
74. Nehs MA, Nagarkatti S, Nucera C, Hodin RA, Parangi S. Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Surgery 148(6), 1154-1162; discussion 1162 (2010
75. Dowlati A, Robertson K, Cooney M et al. A Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 62(12), 3408-3416 (2002 (Pubitemid 34651387)
76. Antonelli A, Bocci G, La Motta C et al. CLM94, a novel cyclic amide with anti- VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J. Clin. Endocrinol. Metab. 97(4), E528-E536 (2012
77. Neff RL, Farrar WB, Kloos RT, Burman KD. Anaplastic thyroid cancer. Endocrinol. Metab. Clin. North Am. 37(2), 525-538, xi (2008 (Pubitemid 351711678)
78. Williams ED. Histogenesis of medullary carcinoma of the thyroid. J. Clin. Pathol. 19(2), 114-118 (1966
79. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 (see comments). Cancer 83(12), 2638-2648 (1998 (Pubitemid 29019586)
80. Paszko Z, Sromek M, Czetwertynska M et al. The occurrence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindred's from Central Poland. Cancer Invest. 25(8), 742-749 (2007 (Pubitemid 350223181)
81. Pelizzo MR, Boschin IM, Bernante P et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur. J. Surg. Oncol. 33(4), 493-497 (2007 (Pubitemid 46586095)
82. Donis-Keller H, Dou S, Chi D et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 2(7), 851-856 (1993 (Pubitemid 23216611)
83. Gimm O, Ukkat J, Niederle BE et al. Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J. Surg. 28(12), 1312-1316 (2004 (Pubitemid 40941298)
84. Kloos RT, Eng C, Evans DB et al. Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid 19(6), 565-612 (2009
85. Bugalho MJ, Domingues R, Santos JR, Catarino AL, Sobrinho L. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery 141(1), 90-95 (2007 (Pubitemid 44918073)
86. Eng C, Mulligan LM, Smith DP et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin. Endocrinol. (Oxf.). 43(1), 123-127 (1995
87. Elisei R, Bottici V, Luchetti F et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: Experience in 10,864 patients with nodular thyroid disorders. J. Clin. Endocrinol. Metab. 89(1), 163-168 (2004 (Pubitemid 38183876)
88. Scollo C, Baudin E, Travagli JP et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J. Clin. Endocrinol. Metab. 88(5), 2070-2075 (2003 (Pubitemid 36549878)
89. Kebebew E, Greenspan FS, Clark OH, Woeber KA, Grunwell J. Extent of disease and practice patterns for medullary thyroid cancer. J. Am. Coll. Surg. 200(6), 890-896 (2005 (Pubitemid 40744797)
90. Modigliani E, Cohen R, Campos JM et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin. Endocrinol. (Oxf.). 48(3), 265-273 (1998 (Pubitemid 28137636)
91. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: Demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107(9), 2134-2142 (2006 (Pubitemid 44665646)
92. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 90(11), 6077-6084 (2005 (Pubitemid 41606528)
93. Engelbach M, Gorges R, Forst T et al. Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. J. Clin. Endocrinol. Metab. 85(5), 1890-1894 (2000 (Pubitemid 32269294)
94. Franc S, Niccoli-Sire P, Cohen R et al. Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin. Endocrinol. (Oxf.) 55(3), 403-409 (2001 (Pubitemid 32823051)
95. Tisell LE, Dilley WG, Wells SA Jr. Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels. Surgery 119(1), 34-39 (1996 (Pubitemid 26029171)
96. Ong SC, Schoder H, Patel SG et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J. Nucl. Med. 48(4), 501-507 (2007 (Pubitemid 47571403)
97. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur. J. Nucl. Med. 28(1), 64-71 (2001 (Pubitemid 32120808)
98. Koopmans KP, De Groot JW, Plukker JT et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J. Nucl. Med. 49(4), 524-531 (2008 (Pubitemid 351520599)
99. Cox TM, Fagan EA, Hillyard CJ, Allison DJ, Chadwick VS. Role of calcitonin in diarrhoea associated with medullary carcinoma of the thyroid. Gut 20(7), 629-633 (1979 (Pubitemid 9220609)
100. Lupoli G, Cascone E, Arlotta F et al. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon a-2b and octreotide. Cancer 78(5), 1114-1118 (1996 (Pubitemid 26284878)
101. Vitale G, Tagliaferri P, Caraglia M et al. Slow release lanreotide in combination with interferon-a2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 85(3), 983-988 (2000 (Pubitemid 32269337)
102. Fromigue J, De Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M. Chemoembolization for liver metastases from medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 91(7), 2496-2499 (2006 (Pubitemid 44024606)
103. Lorenz K, Brauckhoff M, Behrmann C et al. Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery 138(6), 986-993; discussion 993 (2005 (Pubitemid 41797336)
104. Bajetta E, Rimassa L, Carnaghi C et al. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 83(2), 372-378 (1998 (Pubitemid 28317819)
105. Di Bartolomeo M, Bajetta E, Bochicchio AM et al. A Phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. Ann. Oncol. 6(1), 77-79 (1995
106. Petursson SR. Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer 62(9), 1899-1903 (1988 (Pubitemid 18261811)
107. Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br. J. Cancer 71(2), 363-365 (1995
108. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: Analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6(4), 305-310 (1996 (Pubitemid 26303135)
109. Fersht N, Vini L, A'hern R, Harmer C. The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer. Thyroid 11(12), 1161-1168 (2001 (Pubitemid 34041897)
110. Fife KM, Bower M, Harmer CL. Medullary thyroid cancer: The role of radiotherapy in local control. Eur. J. Surg. Oncol. 22(6), 588-591 (1996 (Pubitemid 27036198)
111. Nguyen TD, Chassard JL, Lagarde P et al. Results of postoperative radiation therapy in medullary carcinoma of the thyroid: A retrospective study by the French Federation of Cancer Institutes - the Radiotherapy Cooperative Group. Radiother. Oncol. 23(1), 1-5 (1992
112. Schlumberger M, Parmentier C, Delisle MJ, Couette JE, Droz JP, Sarrazin D. Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 67(3), 564-566 (1991
113. Schwartz DL, Rana V, Shaw S et al. Postoperative radiotherapy for advanced medullary thyroid cancer - local disease control in the modern era. Head Neck 30(7), 883-888 (2008 (Pubitemid 352008948)
114. Kraeber-Bodere F, Salaun PY, Oudoux A, Goldenberg DM, Chatal JF, Barbet J. Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer. Cancer 116(Suppl. 4), S1118-S1125 (2010
115. Juweid ME, Hajjar G, Stein R et al. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J. Nucl. Med. 41(1), 93-103 (2000 (Pubitemid 30046689)
116. Juweid ME, Hajjar G, Swayne LC et al. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer 85(8), 1828-1842 (1999 (Pubitemid 29169686)
117. Santoro M, Melillo RM, Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur. J. Endocrinol. 155(5), 645-653 (2006 (Pubitemid 44857487)
118. Vidal M, Wells S, Ryan A, Cagan R. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res. 65(9), 3538-3541 (2005 (Pubitemid 40616327)
119. Salvatore G, De Falco V, Salerno P et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin. Cancer Res. 12(5), 1623-1629 (2006
120. Carlomagno F, Anaganti S, Guida T et al. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl Cancer Inst. 98(5), 326-334 (2006 (Pubitemid 43338212)
121. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92(3), 205-216 (2000 (Pubitemid 30099779)
122. Pennell NA, Daniels GH, Haddad RI et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18(3), 317-323 (2008 (Pubitemid 351415790)
123. Carr LL, Mankoff DA, Goulart BH et al. Phase II study of daily sunitinib in FDGPET- positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin. Cancer Res. 16(21), 5260-5268 (2010
124. Wells SA Jr, Robinson BG, Gagel RF et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind Phase III trial. J. Clin. Oncol. 30(2), 134-141 (2011
125. Bible KC, Suman VJ, Molina JR et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a Phase 2 consortium study. Lancet Oncol. 11(10), 962-972 (2010
126. Hoftijzer H, Heemstra KA, Morreau H et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 161(6), 923-931 (2009
127. Lam ET, Ringel MD, Kloos RT et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J. Clin. Oncol. 28(14), 2323-2330 (2010
128. Kurzrock R, Sherman SI, Ball DW et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J. Clin. Oncol. 29(19), 2660-2666 (2011
129. Villanueva J, Vultur A, Lee JT et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18(6), 683-695 (2010
130. Hong DS, Cabanillas ME, Wheler J et al. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J. Clin. Endocrinol. Metab. 96(4), 997-1005 (2011
131. Yeung SC, She M, Yang H, Pan J, Sun L, Chaplin D. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J. Clin. Endocrinol. Metab. 92(8), 2902-2909 (2007 (Pubitemid 47236348)
132. Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology 148(3), 948-953 (2007
133. Puppin C, D'aurizio F, D'elia AV et al. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology 146(9), 3967-3974 (2005
134. Sherman EJ, Fury MG, Tuttle RM et al. Phase II study of depsipeptide (DEP) in raioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma. J. Clin. Oncol. 27(Suppl.), Abstract 6059 (2009
135. Ain KB, Lee C, Williams KD. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 17(7), 663-670 (2007 (Pubitemid 47311556)
136. Ain KB, Lee C, Holbrook KM, Dziba JM, Williams KD. Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: Preliminary results. J. Clin. Oncol. 26(Suppl.), Abstract 6027 (2008
137. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2), 281-297 (2004
138. Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103(7), 2257-2261 (2006 (Pubitemid 43271657)
139. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6(11), 857-866 (2006 (Pubitemid 44629897)
140. Pallante P, Visone R, Ferracin M et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr. Relat. Cancer 13(2), 497-508 (2006 (Pubitemid 43886672)
141. Brest P, Lassalle S, Hofman V et al. MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Endocr. Relat. Cancer 18(6), 711-719 (2011
142. Kashima K, Yokoyama S, Noguchi S et al. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 8(3), 197-202 (1998 (Pubitemid 28145182)
143. Kim EY, Kim WG, Kim WB et al. Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin. Endocrinol. (Oxf.). 71(4), 581-586 (2009
144. Papewalis C, Wuttke M, Jacobs B et al. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma. Horm. Metab. Res. 40(2), 108-116 (2008 (Pubitemid 351363421)
145. Schott M, Seissler J, Lettmann M, Fouxon V, Scherbaum WA, Feldkamp J. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J. Clin. Endocrinol. Metab. 86(10), 4965-4969 (2001 (Pubitemid 33020550)
146. Sbiera S, Wortmann S, Fassnacht M. Dendritic cell based immunotherapy - a promising therapeutic approach for endocrine malignancies. Horm. Metab. Res. 40(2), 89-98 (2008 (Pubitemid 351363419)
147. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer 6(4), 292-306 (2006
148. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 66(2), 321-330 (1990 (Pubitemid 20205915)
149. Dumont JE, Lamy F, Roger P, Maenhaut C. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol. Rev. 72(3), 667-697 (1992
150. Nikiforova MN, Ciampi R, Salvatore G et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett. 209(1), 1-6 (2004 (Pubitemid 38656111)
151. Todaro M, Iovino F, Eterno V et al. Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res. 70(21), 8874-8885 (2010
152. Davies TF, Latif R, Minsky NC, Ma R. Clinical review: The emerging cell biology of thyroid stem cells. J. Clin. Endocrinol. Metab. 96(9), 2692-2702 (2011
153. Reis-Filho JS, Preto A, Soares P, Ricardo S, Cameselle-Teijeiro J, Sobrinho-Simoes M. p63 expression in solid cell nests of the thyroid: further evidence for a stem cell origin. Mod. Pathol. 16(1), 43-48 (2003 (Pubitemid 36152685)
154. Malaguarnera R, Mandarino A, Mazzon E et al. The p53-homologue p63 may promote thyroid cancer progression. Endocr. Relat. Cancer 12(4), 953-971 (2005 (Pubitemid 41815789)
155. Ishikawa F, Yoshida S, Saito Y et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 25(11), 1315-1321 (2007 (Pubitemid 350076512)
156. Zheng X, Cui D, Xu S, Brabant G, Derwahl M. Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: Characterization of resistant cells. Int. J. Oncol. 37(2), 307-315 (2010
157. Wang X, Kruithof-De Julio M, Economides KD et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461(7263), 495-500 (2009
158. Morrison R, Schleicher SM, Sun Y et al. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J. Oncol. 2011, 941876 (2010
159. Liu D, Hou P, Liu Z, Wu G, Xing M. Genetic alterations in the phosphoinositide 3-kinase/ Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res. 69(18), 7311-7319 (2009
160. Cohen EE, Rosen LS, Vokes EE et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a Phase II study. J. Clin. Oncol. 26(29), 4708-4713 (2008
161. De Groot JW, Zonnenberg BA, Van Ufford-Mannesse PQ et al. A Phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 92(9), 3466-3469 (2007 (Pubitemid 47435321)
162. Sherman SI, Wirth LJ, Droz JP et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N. Engl. J. Med. 359(1), 31-42 (2008 (Pubitemid 351931094)
163. Schlumberger MJ, Elisei R, Bastholt L et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J. Clin. Oncol. 27(23), 3794-3801 (2009